Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|October 6, 2020

Applying CBT to Psychiatry

Author(s)Judith S. Beck, PhD

Judith Beck, PhD, talks Cognitive Behavior Therapy, clinical tips, and the work of her father, Dr Aaron Beck.

Dr Beck is President of the Beck Institute for Cognitive Behavior Therapy in Philadelphia and is a Clinical Professor of Psychology and Psychiatry at the University of Pennsylvania.

Learn more about the Beck Institute here.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Collaborative Psychiatric-Dermatologic Care Improves Outcomes for Complex Patients

Collaborative Psychiatric-Dermatologic Care Improves Outcomes for Complex Patients

ByJames A. Bourgeois, OD, MD,Xiaofeng Yan, MD, PhD

August 21st 2026

How Does the Skin-Brain Connection Drive Skin-Picking Disorder?

How Does the Skin-Brain Connection Drive Skin-Picking Disorder?

ByJames A. Bourgeois, OD, MD,Xiaofeng Yan, MD, PhD

August 20th 2026

brain injury

Restoring Emotional Self-Awareness After Brain Injury: Research Explores Novel Approach

ByDawn Neumann, PhD, FACRM

July 24th 2026

1 expert is featured in this series.

Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy

ByDavid Walling, PhD

July 8th 2026

1 expert is featured in this series.

Managing Tolerability and Setting Patients Up for Success with Cobenfy

ByDavid Walling, PhD

July 1st 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

August 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News

Presenting Our September 2026 Theme: Depressive Disorders

Novel Serotonergic Agonist, HLP003, Targets the Adjunctive MDD Treatment Gap

Phase 2 Trial of Bezisterim for Neurological Symptoms of Long COVID: Treatment Phase Completed